📊 AEMD Key Takeaways
Is Aethlon Medical Inc. (AEMD) a Good Investment?
Aethlon Medical is a pre-commercial or severely distressed medtech company with only $97.1K in annualized revenue against $7.2M net losses and negative $7.0M operating cash flow, indicating unsustainable burn. With negative margins exceeding -7300% and only $5.0M in cash reserves, the company requires immediate commercialization success or significant capital injection to avoid depletion of resources.
Aethlon Medical’s fundamentals are very weak: revenue is negligible relative to its cost base, operating and net losses are extremely large, and free cash flow is deeply negative. While the balance sheet is currently supported by high cash balances, strong liquidity, and no meaningful debt, the business lacks evidence of durable revenue generation and remains dependent on cash consumption rather than operating traction.
Aethlon Medical Inc. Key Strengths (AEMD)
- Strong liquidity position with 3.85x current ratio and $5.0M cash on hand
- Zero long-term debt, minimizing financial obligations
- Minimal capital expenditure ($3.7K) suggests already-developed product or pre-launch stage
- Strong near-term liquidity with $6.96M in cash and a 5.68x current ratio
- Low financial leverage with essentially no long-term debt
- Positive equity base of $6.71M provides some balance-sheet cushion
AEMD Stock Risks: Aethlon Medical Inc. Investment Risks
- Catastrophic cash burn of $7.0M annually against $97.1K revenue with no profitability path visible
- Operating losses of $7.3M represent -7509% operating margin indicating fundamental business model failure at current scale
- Cash runway exhaustion likely within 8-12 months at current burn rate, necessitating dilutive financing or bankruptcy
- Negative ROE of -146.4% and ROA of -112.9% demonstrate value destruction for shareholders
- Revenue base is extremely small at $97.13K versus $5.27M net loss, indicating poor commercial scale
- Operating cash burn of $5.25M materially pressures runway if revenue does not improve
- Margins, ROA, and ROE are deeply negative, signaling weak growth quality and poor capital efficiency
Key Metrics to Watch
- Quarterly revenue growth trajectory and customer acquisition
- Monthly cash burn rate and updated cash runway estimate
- Operating expense reduction initiatives or new financing announcements
- Quarterly revenue growth and evidence of commercial adoption
- Operating cash burn relative to cash balance
Aethlon Medical Inc. (AEMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.85x current ratio provides a solid financial cushion.
AEMD Profit Margin, ROE & Profitability Analysis
AEMD vs Healthcare Sector: How Aethlon Medical Inc. Compares
How Aethlon Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aethlon Medical Inc. Stock Overvalued? AEMD Valuation Analysis 2026
Based on fundamental analysis, Aethlon Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aethlon Medical Inc. Balance Sheet: AEMD Debt, Cash & Liquidity
AEMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aethlon Medical Inc.'s revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $-85.77 indicates the company is currently unprofitable.
AEMD Revenue Growth, EPS Growth & YoY Performance
AEMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$2.0M | $-0.12 |
| Q1 2023 | N/A | -$2.1M | $-0.14 |
| Q3 2022 | $17.1K | -$1.4M | N/A |
| Q2 2022 | N/A | -$1.4M | $-0.13 |
| Q3 2021 | $413.5K | -$819.6K | N/A |
| Q2 2021 | N/A | -$1.4M | N/A |
| Q1 2021 | N/A | -$1.4M | N/A |
| Q3 2020 | N/A | -$819.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aethlon Medical Inc. Dividends, Buybacks & Capital Allocation
AEMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aethlon Medical Inc. (CIK: 0000882291)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AEMD
What is the AI rating for AEMD?
Aethlon Medical Inc. (AEMD) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AEMD's key strengths?
Claude: Strong liquidity position with 3.85x current ratio and $5.0M cash on hand. Zero long-term debt, minimizing financial obligations. ChatGPT: Strong near-term liquidity with $6.96M in cash and a 5.68x current ratio. Low financial leverage with essentially no long-term debt.
What are the risks of investing in AEMD?
Claude: Catastrophic cash burn of $7.0M annually against $97.1K revenue with no profitability path visible. Operating losses of $7.3M represent -7509% operating margin indicating fundamental business model failure at current scale. ChatGPT: Revenue base is extremely small at $97.13K versus $5.27M net loss, indicating poor commercial scale. Operating cash burn of $5.25M materially pressures runway if revenue does not improve.
What is AEMD's revenue and growth?
Aethlon Medical Inc. reported revenue of $97.1K.
Does AEMD pay dividends?
Aethlon Medical Inc. does not currently pay dividends.
Where can I find AEMD SEC filings?
Official SEC filings for Aethlon Medical Inc. (CIK: 0000882291) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AEMD's EPS?
Aethlon Medical Inc. has a diluted EPS of $-10.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AEMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aethlon Medical Inc. has a D grade with 89% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AEMD stock overvalued or undervalued?
Valuation metrics for AEMD: ROE of -146.4% (sector avg: 15%), net margin of -7,362.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AEMD's AI grade for 2026?
Our dual AI analysis gives Aethlon Medical Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AEMD's free cash flow?
Aethlon Medical Inc.'s operating cash flow is $-7.0M, with capital expenditures of $3.7K. FCF margin is -7,208.8%.
How does AEMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,362.6% (avg: 12%), ROE -146.4% (avg: 15%), current ratio 3.85 (avg: 2).